PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery

Gu, Shanshan, Cui, Danrui, Chen, Xiaoyu, Xiong, Xiufang, Zhao, Yongchao·2018·BioEssays
DOI 10.1002/bies.201700247

Cited by (239)

Items 201–239 of 239

  1. OTX015 PROTACs: Emerging Novel Therapeutic Agents in Cancer Treatment
    Rajwinder Kaur, Pargat Singh, Amritpal Kaur, Gaurav Chaudhary, Diksha Choudhary, Paranjeet Kaur, Sanjeev Kumar Sahu · 2024 · BIO Web of Conferences
  2. Toxicological Aspects of PROTACs
    Rohini Pujari, Urvashi Soni · 2024 · Springer eBooks
  3. Extending the chemical space of glutarimide-based cereblon ligands through an efficient Rh(II)-catalyzed X–H insertion reaction
    Ekaterina Levashova, Luca Bischof, Alexander Siyasatovich Bunev, Alexander Sapegin, Olga Grygor'eva, Andrey Yu Kudinov, Sebastian Ebeling, Ilya Tatarinov, Dmitry Viktorovich Dar’in, Grigory P. Kantin et al. · 2025 · European Journal of Medicinal Chemistry
  4. Structural and Biophysical Principles of Degrader Ternary Complexes
    David Zollman, Alessio Ciulli · 2020 · Royal Society of Chemistry eBooks
  5. Application of PROTACs in the Pharmaceutical Direction
    Ke Zhou, Li Zhang, Yi Liu · 2023 · International Journal of Biology and Life Sciences
  6. Development of LYTACs via incorporating a nucleolin-targeting and lysosome-directed aptamer
    Fang Qiu, Ziting Feng, Hongzhen Chen, Xiaoxuan Zhang, Jianmin Guo, Chunhao Cao, Aiping Lü, Chao Liang · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  7. Exploring Novel Approaches Towards Anti-Cancer Galectin-3 Chemotherapeutics
    Ashleigh R Ross · 2020 · Griffith Research Online
  8. Cancer Targets Involving the Ubiquitin Proteasome System
    Erika M. V. Araujo · 2021 · Burger's Medicinal Chemistry and Drug Discovery
  9. LSD1 Destabilizes FBXW7 Independent of Its Demethylase Activity
    Huiyin Lan, Mingjia Tan, Qiang Zhang, Fei Yang, Hua Li, Xiufang Xiong, Yi Sun · 2018 · SSRN Electronic Journal
  10. Future Possibilities
    John B. Bremner · 2021 · Springer eBooks
  11. Hitting a Moving Target
    Emile P. Chen · 2025 · Wiley eBooks
  12. Future Perspectives and Challenges in the Field of Proteostasis and Neurodegenerative Disorders
    Suruchi Chaudhary, Vikas Shrivastava, Manish Kumar, Ekansh Agrawal, Niharika Singh, Rajesh Singh Tomar · 2025 · Springer eBooks
  13. Lysosome-mediated degradation
    Wenhai Huang · 2025 · Elsevier eBooks
  14. Programmed Targeted Protein Degradation Via DNA Modularized Ligand
    Xuanming Teng, Jingyi Yang, Zhiyi Ren, Yan Sha, Jiaxin Zhai, Xinyuan Hu, Shule Hou, Yangyang Y. Yang · 2025 · ChemMedChem
  15. New modalities: Drugging the undruggable GPCR targets
    P. Zawadzki, Piotr P. Graczyk, Jakub Staroń · 2025 · Elsevier eBooks
  16. PROTACS- targeted protein degradation as a path to precision cancer therapeutics
    Hannah R Gatley, Paul B. Fisher, Swadesh Kumar Das · 2025 · Advances in cancer research
  17. Thalidomide-Based PROTACs: A Viable Strategy Against Trypanosomatids?
    Romina Manarin, Gianfranco Frattini, Victoria Lucía Alonso, Victoria Boselli, Giselle Bedogni, Elvio Rodríguez Araya, Diego Martín Moreno, Esteban Carlos Serra · 2025 · Drugs and Drug Candidates
  18. Research Advances in KRAS Mutation Cancer Treatment Strategies: From “Undruggable” Targets to Diversified Precision Therapies
    含笑 朱 · 2026 · Advances in Clinical Medicine
  19. Advancing Targeted Protein Degradation Through Immunoproteasome‐Caged N‐Degrons
    Jack S. White, Michael M. Shahid, Mohamed A. Eldeeb · 2026 · ChemBioChem
  20. Profilage de l'ubiquitylation des protéines dans les cellules résistantes au bortézomib : rôle des enzymes de ubiquitylation
    María Gonzalez-Santamarta · 2022 · theses.fr (ABES)
  21. Proteolysis targeting chimeras (PROTAC) for targeting Alzheimer’s disease
    Archna Singh, Anjna Rani, Avijit Mazumder · 2026 · Discover Neuroscience
  22. Degraders of histone lysine methyltransferases: Progress, challenges, and opportunities
    Mengling Yang, Qiangsheng Zhang, Jing Yang, Ruini Cheng, Xianli Zhou · 2026 · Drug Discovery Today
  23. Targeted protein degradation: mechanistic diversity, therapeutic expansion, and clinical translation
    Caiyu Wang, Zhibin Guo, Yufei Liu, Qichao Gao, Qing Wang, Yi Liu, Yujiao Liu · 2026 · International Journal of Pharmaceutics
  24. Rational design of PROTACs empowered by deep generative modeling: current advances and future perspectives
    Rui Zhou, Sisi Yang, Yifan Chen, Li Wang, Xiangzheng Fu, Dongsheng Cao, Xiaojun Yao · 2026 · International Journal of Biological Macromolecules
  25. BindingDB Entry 50022943: Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy.
    BindingDB · 2026 · UC San Diego
  26. BindingDB Entry 50018659: Developments of CRBN-based PROTACs as potential therapeutic agents.
    BindingDB · 2024 · UC San Diego
  27. BindingDB Entry 50020587: Small Molecule Inhibitors Targeting the "Undruggable" Survivin: The Past, Present, and Future from a Medicinal Chemist's Perspective.
    BindingDB · 2024 · UC San Diego
  28. BindingDB Entry 50018341: A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.
    BindingDB · 2024 · UC San Diego
  29. BindingDB Entry 50007038: Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
    BindingDB · 2021 · UC San Diego
  30. BindingDB Entry 50015612: Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies.
    BindingDB · 2023 · UC San Diego
  31. BindingDB Entry 50016839: VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.
    BindingDB · 2023 · UC San Diego
  32. BindingDB Entry 50021366: Development of Degraders of Cyclin-Dependent Kinases 4 and 6 Based on Rational Drug Design.
    BindingDB · 2025 · UC San Diego
  33. BindingDB Entry 50016375: Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
    BindingDB · 2023 · UC San Diego
  34. BindingDB Entry 50016393: Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance.
    BindingDB · 2023 · UC San Diego
  35. BindingDB Entry 50016515: Nucleic-Acid-Based Targeted Degradation in Drug Discovery.
    BindingDB · 2023 · UC San Diego
  36. BindingDB Entry 50021317: Progress in the controllability technology of PROTAC.
    BindingDB · 2025 · UC San Diego
  37. BindingDB Entry 50019179: Targeted Protein Degradation Induced by HEMTACs Based on HSP90.
    BindingDB · 2024 · UC San Diego
  38. BindingDB Entry 50020203: Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues.
    BindingDB · 2024 · UC San Diego
  39. BindingDB Entry 50021132: Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    BindingDB · 2025 · UC San Diego